PMC · DOI:10.3892/or.2026.9066·February 2, 2026
[Retracted] EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo
Yiting Jin, Wei Zhang, Hongying Wang, Zijing Zhang, Chengyu Chu, Xiuping Liu, Qiang Zou
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Proteins3
Chemicals4
Diseases1
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHER2/EGFR in Cancer Research · Drug Transport and Resistance Mechanisms · Breast Cancer Treatment Studies